



Press Release

CELEOS Announces its First €1.5M Funding Round to Revolutionize Cancer Surgical Guidance

Lille, July 24, 2025 - CELEOS, a Deeptech / MedTech startup emerging from the Lille ecosystem, announces the closing of its first seed fundraising round of **€1.5 million**. This strategic operation aims to finalize its integrated real-time surgical guidance device prototype, ready for human testing and designed to improve precision in oncology surgeries.

A structured fundraising round supported by key players

The funding consists of:

- € 527,000 in *equity*,
- € 300, 000 in convertible bonds via the French Tech Seed program,
- € 700,000 in grants and repayable advances.

Investors include **Business Angels**, **SATT Nord**, and the **Centre Oscar Lambret**, which is acquiring a stake in a company for the first time in its history. CELEOS was supported in this operation by **Eurasanté**, **Link Gestion** et **Pledge Avocats**.

« This funding allows us to reach a key milestone: achieving a functional and integrated prototype, with a view to our clinical validation in the operating room. Our ambition is clear: to offer surgeons a precision tool to improve the chances of recovery for cancer patients », states Philippe Saudemont, PhD, co-founder and CEO of CELEOS.

A technology born from academic research

Founded in **2023** by Dr. Philippe Saudemont and four partners, CELEOS is the result of over ten years of research conducted at the PRISM laboratory of the **University of Lille**. The startup is developing a surgical guidance technology using mass spectrometry, capable of identifying the nature of tissues (healthy or cancerous) in a matter of seconds during surgery.

An intelligent surgical co-pilot

The technology, originally named **SpiderMass**, will take the form of a **mobile cart** integrating a **laser**, a **mass spectrometer**, and **artificial intelligence**. The laser vaporizes the tissue surface, generating vapors containing a true molecular fingerprint of the tissue. This is analyzed in real-time by AI, which then provides the surgeon with a clear and immediate response to guide their surgical decision

A major medical and economic challenge

CELEOS – Place de Verdun, Bâtiment IRCL. 59000 LILLE

Société par Actions Simplifiée, au Capital de 82 590 € - N° identification 950 877 407 RCS LILLE Métropole



Today, intraoperative analyses take a **minimum of 40 minutes**, when they can be performed at all, and definitive results can require **up to 4 weeks**. These delays lead to a **surgical reintervention rate of 20 to 45%**, with back-and-forth between the operating room and the pathology laboratory, and sometimes the inability to reach a conclusion on samples of limited size.

CELEOS's solution aims to:

- **Reduce intraoperative uncertainties,**
- **Decrease relapses and complementary treatments,**
- **Optimize hospital resources,**
- **Relieve pathology laboratories.**

To learn more about CELEOS and follow the project's progress, visit <https://www.celos.ai> and our [LinkedIn page](#).

CONTACT

Philippe Saudemont
Co-Fondateur et CEO

E-mail : philippe.saudemont@celos.ai